Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 4.64% and Operating profit at 14.49% over the last 5 years
2
The company has declared Positive results for the last 4 consecutive quarters
3
With ROE of 12.47%, it has a very attractive valuation with a 1.22 Price to Book Value
4
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
CNY 15,352 Million (Large Cap)
10.00
NA
2.31%
-0.20
10.20%
1.39
Revenue and Profits:
Net Sales:
2,372 Million
(Quarterly Results - Sep 2025)
Net Profit:
242 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
18.27%
0%
18.27%
6 Months
1.35%
0%
1.35%
1 Year
7.74%
0%
7.74%
2 Years
70.47%
0%
70.47%
3 Years
26.78%
0%
26.78%
4 Years
8.87%
0%
8.87%
5 Years
7.46%
0%
7.46%
Zhejiang Medicine Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.64%
EBIT Growth (5y)
14.49%
EBIT to Interest (avg)
22.72
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.15
Sales to Capital Employed (avg)
0.77
Tax Ratio
15.15%
Dividend Payout Ratio
30.66%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.04%
ROE (avg)
7.35%
Valuation key factors
Factor
Value
P/E Ratio
10
Industry P/E
Price to Book Value
1.22
EV to EBIT
7.89
EV to EBITDA
5.25
EV to Capital Employed
1.27
EV to Sales
1.28
PEG Ratio
0.04
Dividend Yield
2.59%
ROCE (Latest)
16.10%
ROE (Latest)
12.47%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
2,372.40
2,067.50
14.75%
Operating Profit (PBDIT) excl Other Income
244.40
427.70
-42.86%
Interest
6.40
6.30
1.59%
Exceptional Items
20.10
3.40
491.18%
Consolidate Net Profit
242.20
239.30
1.21%
Operating Profit Margin (Excl OI)
103.00%
113.80%
-1.08%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 14.75% vs -8.33% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 1.21% vs -37.89% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
9,325.60
7,760.30
20.17%
Operating Profit (PBDIT) excl Other Income
2,018.30
756.80
166.69%
Interest
35.40
35.60
-0.56%
Exceptional Items
-112.90
-34.50
-227.25%
Consolidate Net Profit
1,020.30
276.80
268.61%
Operating Profit Margin (Excl OI)
138.80%
3.80%
13.50%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 20.17% vs -3.95% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 268.61% vs -23.66% in Dec 2023
About Zhejiang Medicine Co., Ltd. 
Zhejiang Medicine Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






